MUSK and myasthenia gravis: Comparison of MG-ADL, QMG, and MGC scores at different time points before treatment and at 1, 3, 6, and 12 months after ofatumumab treatment in 5 MuSK antibody-positive patients and 9 AChR antibody-positive patients.